Mirum Pharmaceuticals, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Mirum Pharmaceuticals, Inc. (MIRM) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $14.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-25
- Mirum Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $14.40M, a 40.50% decline from fiscal 2024.
- Mirum Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $24.20M, a 39.80% decline from fiscal 2023.
- Mirum Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $40.20M, a 23.69% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $32.50M, a 35.98% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 8 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|
| 2025-12-31 | $14.40M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $24.20M 10-K · filed 2026-02-25 | |
| 2023-12-31 | $40.20M 10-K · filed 2026-02-25 | |
| 2022-12-31 | $32.50M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $23.90M 10-K · filed 2024-03-15 | |
| 2020-12-31 | $27.80M 10-K · filed 2022-03-09 | |
| 2019-12-31 | $13.60M 10-K · filed 2021-03-09 | |
| 2018-12-31 | $5.20M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |